HIV-1 peptide–Major Histocompatibility Complex Class I (HIV-1 pHMC) (HIV-1 pHMC)

HIV-1 peptide–Major Histocompatibility Complex (pHMC) complexes are essential molecular assemblies on the surface of infected cells that signal the presence of intracellular Human Immunodeficiency Virus type 1 (PMID: 25673713). These complexes are formed when viral proteins, such as Gag, Pol, or Env, are proteolytically processed into short peptides and loaded onto MHC Class I molecules within the endoplasmic reticulum before being transported to the plasma membrane (UniProt: P01889). The primary biological role of these complexes is to serve as ligands for the T-cell receptors (TCRs) of CD8+ cytotoxic T lymphocytes, which then initiate the destruction of the infected cell (PMID: 28834711). In the context of HIV-1 pathology, the virus employs the Nef protein to downregulate MHC Class I expression, thereby reducing the density of pHMCs and evading immune detection (PMID: 8684460). Modern therapeutic interventions, including TCR-like antibodies and Chimeric Antigen Receptor (CAR) T-cells, are being developed to target these complexes with high specificity and affinity (PMID: 31160314). These TCR-mimetic strategies are particularly valuable for targeting the HIV-1 reservoir, as they allow for the recognition of internal viral antigens that are not accessible to traditional neutralizing antibodies. By targeting conserved epitopes like the Gag-derived SL9 peptide presented by HLA-A*02, these therapies aim to eliminate latently infected cells upon reactivation (PMID: 25673713).

Other names

HIV-1 pMHCHIV-1 peptide-HLA complexHIV-1 epitope-MHC complexHIV-1 pHLA

Recognition of intracellularly derived viral peptides presented on the cell surface to trigger targeted lysis of infected cells by cytotoxic T lymphocytes or engineered immune cells.